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Economic evidence for the clinical management of
major depressive disorder: a systematic review and
quality appraisal of economic evaluations alongside
randomised controlled trials
E. Karyotaki1,2*†, D. Tordrup3*†, C. Buntrock1,2,4, R. Bertollini5 and P. Cuijpers1,2
1 Department of Clinical Psychology, VU Amsterdam, Amsterdam, The Netherlands
2 EMGO, Institute of Health Care Research, VU Medical Centre, Amsterdam, The Netherlands
3 Division of Pharmacoepidemiology and Clinical Pharmacology, Utrecht WHO Collaborating Centre for Pharmaceutical Policy and Regulation,
University of Utrecht, The Netherlands
4 Division Health Trainings Online, Leuphana University Innovation Incubator, Lüneburg, Germany
5 Representation to the EU, WHO, Brussels, Belgium
Aims. The aim of this systematic review of economic evaluations alongside randomised controlled trials (RCTs) was to
provide a comprehensive overview of the evidence concerning cost-effectiveness analyses of common treatment options
for major depression.
Methods. An existing database was used to identify studies reporting cost-effectiveness results from RCTs. This data-
base has been developed by a systematic literature search in the bibliographic databases of PubMed, PsychINFO,
Embase and Cochrane library from database inception to December 2014. We evaluated the quality of economic evalua-
tions using a 10-item short version of the Drummond checklist. Results were synthesised narratively. The risk of bias of
the included RCTs was assessed, based on the Cochrane risk of bias assessment tool.
Results. Fourteen RCTs were included from the 5580 articles screened on titles and abstracts. The methodological qual-
ity of the health economic evaluations was relatively high and the majority of the included RCTs had low risk of bias in
most of Cochrane items except blinding of participants and personnel. Cognitive behavioural therapy was examined in
seven trials as part of a variety of treatment protocols and seems cost-effective compared with pharmacotherapy in the
long-term. However cost-effectiveness results for the combination of psychotherapy with pharmacotherapy are conflict-
ing and should be interpreted with caution due to limited comparability between the examined trials. For several treat-
ments, only a single economic evaluation was reported as part of a clinical trial. This was the case for comparisons
between different classes of antidepressants, for several types of psychotherapy (behavioural activation, occupational
therapy, interpersonal psychotherapy, short-term psychotherapy, psychodynamic psychotherapy, rational emotive be-
havioural therapy, solution focused therapy), and for transcranial magnetic stimulation v. electroconvulsive therapy.
The limited evidence base for these interventions means generalisations, based on economic evaluation alongside clin-
ical trials, cannot easily be made.
Conclusions. There is some economic evidence underpinning many of the common treatment options for major de-
pression. Wide variability was observed in study outcomes, probably attributable to differences in population, interven-
tions or follow-up periods. For many interventions, only a single economic evaluation alongside clinical trials was
identified. Thus, significant economic evidence gaps remain in the area of major depressive disorder.
Received 8 October 2015; Accepted 29 May 2016
Key words: Depression, mood disorders unipolar, psychotherapy, cognitive therapy.
Introduction
Major depressive disorder (MDD) is one of the most
common conditions worldwide and is associated
with high risk of mortality and morbidity. Lifetime de-
pression prevalence ranges from 3% in Japan to 17% in
the USA, while the majority of countries fall within the
range of 8–12% (Andrade et al. 2003; Kessler et al.
2005). MDD has severe economic consequences for
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individuals and society arising out of increased health-
care utilisation, caregiver burden and labour force
productivity losses (Cuijpers et al. 2012; Lepine &
Briley, 2011). Furthermore, MDD is a major cause of dis-
ease burden throughout the world and is one of the pri-
ority conditions examined under the Research Agenda
for Health Economic Evaluation (RAHEE) project
implemented by the World Health Organization
(WHO) (Tordrup & Bertollini, 2014; Tordrup et al.
2015). The objective of the RAHEE project is to identify
health economic research priorities based on availability
of economic evidence for selected conditions. The pre-
sent review arose as part of this project.
There is ample evidence for the therapeutic effect-
iveness of several forms of therapy in treating MDD.
For instance, several systematic reviews have exam-
ined the effects of pharmacotherapy and psychother-
apy and have demonstrated that both therapeutic
options are effective in treating depressive disorders
in both the short and the long term (Cuijpers et al.
2008a, b, 2010; Cuijpers et al. 2009; Karyotaki et al.
2016). Moreover, research has shown that other treat-
ment alternatives, such as transcranial magnetic stimu-
lation (rTMS), can be effective in treating the
symptoms of MDD (Lee et al. 2012). Considering the
rising health care costs associated with the treatment
of MDD, it is important to further examine the cost-
effectiveness of common treatment options, however
only a few systematic reviews have touched upon this.
Grochtdreis et al. (2015) performed a systematic re-
view of studies examining the cost-effectiveness of col-
laborative care compared with usual care in patients
with depression. The authors found studies were in-
consistent in their quality and results, and conclusions
were ambiguous depending on willingness to pay.
Incremental cost per Quality Adjusted Life Year
(QALY) ranged from dominance to US$ 874 562
Purchasing Power Parity (PPP) (Grochtdreis et al.
2015). Furthermore, Rabheru (2012) searched for cost-
effectiveness evidence of maintenance electroconvul-
sive therapy (M-ECT) in patients who had responded
to ECT but found no trials reporting cost-effectiveness
in a maintenance setting since 1997. In the same year,
Lee et al. (2012) published a review on the clinical and
cost-effectiveness evidence of transcranial magnetic
stimulation (TMS) in the treatment of resistant MDD.
The authors examined four studies, which were in dis-
agreement on the cost-effectiveness of TMS v. ECT. To
the best of our knowledge, there are no recent (carried
out in the past 10 years) systematic reviews on the cost-
effectiveness of psychotherapy or the combination of
pharmacotherapy and psychotherapy in patients with
MDD.
Given the limited evidence on the cost-effectiveness
of treatments for major depression in existing reviews,
the present systematic review of randomised con-
trolled trials (RCTs) seeks to provide a comprehensive
overview of the cost-effectiveness of the most common
treatment options for MDD. We aimed to identify evi-
dence gaps, as well as highlight the methodological




We screened an existing database that was developed
to identify all RCTs on cost-effectiveness outcomes
in the treatment of common mental disorders (depres-
sion and anxiety disorders). This database has been
used in a recently submitted paper, reporting a global
return on investment analysis on mental health for de-
pression and anxiety disorders (Chisholm et al. 2016).
We built the database employing a systematic
literature search in PubMed, PsychINFO, Embase
and Cochrane library from database inception to
December 2014. In these searches, various terms cover-
ing economic evaluation and common mental disor-
ders were used in different combinations, using both
index and free terms. A full search string for
PubMed is provided in Appendix A. In total, 6347
references are included in the database and were
examined for eligibility in the present review (2203
from PubMed, 321 from PsychINFO, 2046 from
Embase and 1777 from the Cochrane library). In add-
ition to this database, we conducted a separate search
in PubMed for verification purposes. Resulting titles
and abstracts were screened for eligibility and full
texts were retrieved and examined for inclusion.
Flow chart 1 shows the study selection process.
Inclusion criteria
Participants: individuals with moderate or severe
MDD (as defined in individual studies). No age or
country restriction was applied.
Intervention: treatment options for MDD – psycho-
therapy, pharmacotherapy, combined psychotherapy
with pharmacotherapy, physical treatments (ECT and
transcranial magnetic stimulation).
Comparison: Control comparison conditions (treat-
ment as usual (TAU) or pill placebo); or active com-
parison conditions (common treatment options for
MDD, as described above).
Outcomes: We included full economic evaluations
reporting outcomes on cost-benefit, cost-effectiveness
and cost-utility. We also considered cost-minimisation
studies of interventions with identical effectiveness (a
special case of cost-effectiveness), and cost-
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consequence studies where one intervention was less
costly and more effective (equivalent to a dominant
intervention in a cost-effectiveness study).
Study design: RCTs
Exclusion criteria
Studies were excluded if they did not integrate cost-
and effectiveness analyses, e.g. cost-consequence or
cost-minimisation studies, except as specified above.
Moreover, we excluded collaborative care interven-
tions since this topic has already been covered by a
recent systematic review (Grochtdreis et al. 2015).
Modelling studies were excluded due to methodo-
logical differences compared with RCT-based econom-
ic evaluations. Further, studies were excluded if the
language was not English. Finally, we did not search
for unpublished data because it was out of the scope
of the present systematic review.
Quality assessment of economic evaluations
We assessed the methodological quality of the eco-
nomic evaluations based on the Drummond 10-item
checklist (Drummond, 2005). For each of the 10
items, studies were scored as ‘yes’, ‘no’, ‘cannot tell’
or ‘not applicable’, the latter being used for items
that were not applicable to certain studies. One author
(C.B.) completed the checklist and another reviewed it
(E.K.). Disagreement was resolved through discussion.
Risk of bias assessment
Furthermore, we assessed the validity of the included
studies according to the Cochrane Collaboration’s
Risk of bias assessment tool (Higgins & Altman,
2011; Higgins & Green, 2011). This tool examines the
following domains of possible bias: (a) selection bias:
systematic differences between groups in baseline
characteristics due to inadequate random sequence
generation or allocation concealment, (b) performance
bias: systematic differences between the groups in the
treatment provided due to the absence of blinding of
participants and personnel, (c) detection bias: system-
atic differences between the groups in how outcomes
were assessed and determined due to the absence of
blinding of outcome assessors, (d) attrition bias: sys-
tematic differences between groups in study dropout
(incomplete outcome data), (e) reporting bias: system-
atic differences between reported and unreported
results (selective reporting), (f) other bias: bias due to
other issues (Higgins and Altman, 2011; Higgins &
Green, 2011).
Data extraction and management
Two authors (E.K. and D.T.) extracted independently
the following data: authors’ names, study setting,
major depression diagnosis status, type and duration
of the therapy, type of control groups and economic
perspective and outcomes. This information is sum-
marised in Table 1. Data from the included studies
are combined narratively and are presented in the fol-
lowing section. This narrative description presents the
main characteristics of the economic evidence. All costs
were inflated to 2014 US$ PPP using OECD and World
Bank country specific Consumer Price Index statistics
and currency conversion rates (OECD, 2016a, b; WB,
2015). 2014 US$ PPP values are given throughout the
paper, with original currencies and values in
[brackets].
Results – data synthesis
Study characteristics
Across the 14 included RCTs (Fig. 1), outpatients were
recruited mainly through clinical samples (n = 12),
while two studies recruited participants through both
community and clinical referrals. The included
studies were conducted in six different countries:
Finland (n = 1), Romania (n = 1), the Netherlands
(n = 3), Japan (n = 1), the UK (n = 5) and the USA
(n = 3). Time horizons for economic outcomes were 2–
36 months. The included RCTs examined eight types
of psychotherapeutic interventions: behavioural acti-
vation (BA; n = 1 study), cognitive behavioural therapy
(CBT; n = 7 studies), interpersonal psychotherapy (IPT;
n = 1 study), occupational therapy (OT; n = 1 study),
psychodynamic psychotherapy (PDT; n = 1 study),
psychoeducation (PEP; n = 2 studies), rational emotive
behavioural therapy (REBT; n = 1 study) and solution
focused therapy (SFT; n = 1 study), while the included
pharmacotherapeutic trials examined mostly antide-
pressants from the cluster of selective serotonin re-
uptake inhibitors (SSRIs). Finally, one trial examined
the effects of TMS compared with ECT. Studies target-
ing absolute efficacy used TAU or pill placebo as con-
trol comparison condition (n = 8 studies). Table 1
presents a summary of study characteristics.
Quality assessment of economic evaluations
The overall methodological quality of the economic
evaluations was relatively good, but varied among
studies. The mean relative value of the methodological
quality criteria fulfilled was 9.7 out of 12 (see Table 2).
The minimum relative value of criteria fulfilled was 8
(Knapp et al. 2008) and the maximum value of criteria
Economic evidence for the clinical management of major depressive disorder 3
Table 1. Study characteristics




(months) Results on cost-effectiveness outcomes Country Perspective
Moderate major depressive disorder
Psychotherapeutic interventions v. other types of psychotherapeutic interventions or control groups
Schene et al.
(2007)
Clinical setting Moderate MDD
(DSM-IV)




42 Compared with TAU:
• OT and TAU did not improve depression
outcomes
• OT and TAU had a 75.5% probability of
being cost-effective (higher net benefit at an
average wage value of US$ 44.74 [US$
36.88]) compared with TAU alone
• OT and TAU resulted in more hours




Clinical setting Moderate MDD
(DSM-IV)





9 • The total costs were US$ 1897 [US$ 1842]
for maintenance TAU and family PEP
compared with US$ 2717 [US$ 2638] for
maintenance TAU group. Differences
between groups were not significant (p =
0.509)
• Maintenance TAU and family PEP had a
90% probability of being cost-effective
compared with maintenance TAU alone if
the decision maker is willing to pay US$ 21
[US$ 20] for 1 additional day free of relapse
JP Health
system











36 • The mean total intervention costs were:
◦ CBT-enhanced PEP: US$ 12 506 [€ 9254]
◦ PEP: US$ 13 265 [€ 9816]
Psychiatrist-enhanced PEP: US$ 13 303
[€ 9844]
◦ TAU: US$ 11 081 [€ 8200]
• No significant differences were observed in
QALY gains
• Up to a willingness-to-pay of US$ 405
[€ 300] for 1 additional depression free day,











Results on cost-effectiveness outcomes Country Perspective
threshold, CBT-enhanced PEP was most











3 • BA yielded significantly higher QALY gain
of 0.20 (95% CI 0.01 to 0.39, p = 0.042)
• ICER of US$ 8301 [£ 5756] per QALY for
BA at 3 months
• 97% probability that BA is cost-effective
compared to TAU at a threshold value of











12 No significant differences in costs or
outcomes were observed
• The mean total direct costs in the S-PDT
group (US$ 1946 [€ 1791]) were 16% lower
than the mean total direct costs in the S-SFT
group (US$ 2322 [€ 2137]). Differences
between groups were not significant (p >
0.05)
• Symptoms were significantly reduced in
both interventions, but with no significant










12 No significant differences in mean total cost
or remission were observed
• IPT group experienced 6% less remission
(MADRS) compared with TAU at 12
months
• Total costs (direct and indirect) were on
average non-significantly higher (US$ 1039
[€ 769]) for IPT
• This resulted in a negative ICER of US$





















Results on cost-effectiveness outcomes Country Perspective
with cost-effect pairs mostly distributed
near the origin and in all four quadrants of
the cost-effectiveness plane















3, 9 • ICER’s over placebo at 12 weeks:
W CBT: US$ 11 866 556 [US$ 9 210 622]
W ADM: US$ 30 582 [US$ 23 737]
W CBT & ADM: US$ 158 652 [US$ 123
143]
• CBT & ADM had more than 90%
probability (at a threshold of US$ 128 836
[US$ 100 000]) of being more cost-effective
than ADM alone at 36 weeks
• CBT is not likely to be more cost-effective




Clinical setting Moderate MDD
(DSM-IV)
• SSRI
• SSRI and CBT
• 168
• 166
6 Combined treatment resulted in 8.3
additional depression free days (p = 0.03)
ICERs:
• US$ 221 [US$ 188] (95%CI US$ -26 [US$
-22] to US$ 1896 [US$ 1613]) per depression
free day
• US$ 167 [US$ 142] (95%CI US$ -16 [US$
-14] to US$ 2973 [US$ 2529]) per depression
improvement day
• US$ 92 812 [US$ 78 948] (95%CI US$ -10
840 [US$ -9221] to US$ 796 418 [US$ 677
448]) per QALY
• 61% probability that combined treatment is
cost- effective at a willingness to pay of US$




Clinical setting Moderate MDD
(DSM-IV)
















Results on cost-effectiveness outcomes Country Perspective
• For CBT and SSRI compared with SSRI
alone, the ICER is US$ 4687 [£ 2873] per
unit increase in HoNOSCA (higher scores
indicate worsening of symptoms)
• There is only 25% probability that CBT and
SSRI is more cost-effective than SSRI alone
at a threshold value of US$ 81 577 [£50 000]










6 • Both CBT and REBT were more
cost-effective per depression free day
gained per month compared with SSRI:
W CBT median: US$ 70.63 [US$ 26.44]
W REBT median: US$ 63.50 [US$ 23.77]
W SSRI median: US$ 93.31 [US$ 34.93]
• Both CBT and REBT exhibited better
cost-utility compared with SSRIs
W CBT: US$ 4375 [US$ 1638]
W REBT: US$ 4632 [US$ 1734]












12 • SSRI resulted in more depression-free days
(mean, 39.7; 95% CI, 12.9–66.5) than the
CBT group (mean, 25.80; 95% CI, 0.04–
51.50) compared with TAU
• The outpatient and medication costs were
US$ 32.49 [US$ 24.65] per additional
depression-free day for pharmacotherapy
and US$ 35.64 [US$ 27.04] for CBT v. TAU.
Total cost (incl. inpatient) was
approximately double
• ICER’s including total costs (outpatient +
inpatient +medication) were US$ 39 570/






















Results on cost-effectiveness outcomes Country Perspective
pharmacotherapy and US$ 49 514 [US$ 37
568] for CBT
Direct comparison between antidepressant agents
Wade et al.
(2008)






6 • Total costs were significantly lower (p <
0.05) for the SSRI (US$ 294 [£ 188])
compared with the SNRI (US$ 522 [£ 334])
• The SSRI was also more effective in terms
of SDS score reduction, with a difference of
2.4 (95% CI 0.4, 4.1) against the SNRI
• Mean sick leave duration was significantly
shorter with the SSRI (30.7 days v. 62.2
days; p = 0.007)
UK Societal












7 • ECT was initially more effective than rTMS
with 59% v. 17% of patients achieving
remission, but no differences were
observed after 6 months follow-up (p =
0.93). Total costs were lower for ECT than
for rTMS (p = 0.04)
• At a willingness-to-pay of US$ 826 [£ 500]
per unit of symptom improvement
(HSRD), there is a 98% probability rTMS is
cost-effective compared with ECT.
However at a willingness-to-pay of zero
per unit of improvement, the probability is
24%.
• At a willingness-to-pay of US$ 49 583 [£ 30
000] per QALY, the probability of rTMS













12 • CBT & TAU resulted in higher QALY gains
of 0.057 (95% CI 0.015–0.099; p < 0.05)








met was 11 (Domino et al. 2008; Lynch et al. 2011;
Maljanen et al. 2012; Hollinghurst et al. 2014). All stud-
ies included a well-defined research question, reported
on the effectiveness of the programme or service con-
cerned, identified all relevant costs and consequences
for each alternative, measured costs and consequences
accurately, and valued the cost credibly. All studies ex-
cept for one (in brackets) included a comprehensive
description of the competing alternatives (Wade et al.
2008), valued the consequences credibly (Byford et al.
2007), performed an incremental analysis of costs and
consequences of alternatives (Knapp et al. 2008), and
included a presentation and discussion of study results
that covered all issues of concern to users (Knapp et al.
2008). Only three studies reported on adjusting cost and
consequences for differential timing (Byford et al. 2007;
Domino et al. 2008; Maljanen et al. 2012). Five studies
did not make allowances for uncertainty in the estima-
tion of costs (Revicki et al. 2005; Bosmans et al. 2007;
Domino et al. 2008; Sava et al. 2009; Ekers et al. 2011).
Only three studies allowed for uncertainty in the esti-
mation of consequences (Domino et al. 2008; Lynch
et al. 2011; Hollinghurst et al. 2014).
Risk-of-bias assessment
With regard to risk-of-bias assessment, the majority of
the included trials reported an adequate random se-
quence generation (11/14). The allocation was concealed
in 6 out of the 14 included RCTs while the remainder
reported inadequate information to permit judgement.
Blinding of personnel and participants was possible in
only one of the included studies and incomplete out-
come data were adequately addressed by 11 included
RCTs. Finally the vast majority of the included trials
were rated as free from selective outcome reporting
bias (13/14) and other sources of bias (14/14) (Fig. 2.)
Moderate major depressive disorder
Psychotherapeutic interventions v. other types of
psychotherapeutic interventions or control groups
One study examined the cost-effectiveness of psycho-
therapeutic interventions targeting work related out-
comes (e.g. productivity losses). Schene et al. (2007)
found that adding OT to TAU did not improve depres-
sion outcomes, but did result in a significant reduction
of workdays lost over 18 months. Net benefit was cal-
culated as the ‘value of work’ (hourly wages multi-
plied by time) minus costs of the intervention. Mean
net benefit was higher in the OT group with a 76%
chance of being cost-effective (higher net benefit)
over usual care at a median wage value of US$ 44.74
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Two studies assessed psychoeducation targeting pre-
vention of MDD relapse/recurrence. A Japanese study
comparing family psychoeducation maintenance treat-
ment with usual care reported significantly more
relapse-free days in the maintenance treatment group.
The intervention was considered cost-effective with a
probability of almost 100% at a willingness-to-pay
(WTP) of US$ 31 [US$ 30] per depression-free day. No
cost-utility results were reported (Shimodera et al.
2012). In contrast, an individual psychoeducation pre-
vention program (PEP) reported by Stant et al. (2009)
in the Netherlands was more expensive and less effect-
ive in terms of depression-free days compared with
TAU. If supplemented with psychiatric consultation or
CBT, outcomes with PEP were slightly better than
TAU, but neither combination was cost-effective.
Follow-up duration was shorter in the Japanese study
(9 months) than in the Dutch study (36 months).
Ekers et al. (2011) conducted a relatively small study
(n = 47 participants) to examine the cost-effectiveness of
BA delivered by non-specialist mental health nurses
compared with TAU. The authors found a significant
difference between groups in QALY’s of 0.20 (95% CI,
0.01–0.39; p = 0.042) in favour of BA and an incremental
cost-utility ratio (ICUR) of US$ 8301/QALY [£5756/
QALY].
Two types of short-term psychotherapy were com-
pared in a Finnish context (PDT and SFT). No significant
differences in costs or effects were observed though
PDT trended towards lower costs and greater improve-
ments.Nocost/QALYwasreported (Maljanen et al.2012).
Management of MDD in elderly (55+) people identi-
fied through primary care screening was assessed by
one study. IPTdid not result in significant clinical change
compared with TAU over 12 months but did incur non-
significantly higher total costs. Uncertainty around the
cost-effectiveness estimate suggested that the interven-
tionwasunlikely tobecost-effective (Bosmans et al.2007).
Combinations of and comparisons between
psychotherapeutic interventions and pharmacotherapy
Eight trials showed conflicting results for the compari-
son of combination therapy (psychotherapy with
Fig. 1. PRISMA Flow chart of the studies selection process.
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pharmacotherapy) with monotherapy (either pharma-
cotherapy or psychotherapy alone). Domino et al.
(2008) compared CBT with fluoxetine (an SSRI) and a
combination of both in a sample of American adoles-
cents with MDD. Compared with pill placebo at 12
weeks, fluoxetine alone was more cost-effective (US$
30 582/QALY [US$ 23 737/QALY]) than fluoxetine
with CBT (US$ 158 652/QALY [US$ 123 143/QALY]).
Furthermore, addition of CBT to fluoxetine was not
cost-effective compared with fluoxetine alone (US$
Table 2. Quality assessment with the 10-item Drummond checklist
Checklist
1. Was a well-defined question posed in answerable form?
2. Was a comprehensive description of the competing alternatives given (i.e. can you tell who did what to whom, where
and how often)?
3. Was the effectiveness of the programme or services established?
4. Were all the important and relevant costs (a) and consequences (b) for each alternative identified?
5. Were costs and consequences measured accurately in appropriate physical units (e.g. hours of nursing time, number of
physician visits, lost work-days, gained life years)?
6. Were the cost (a) and consequences (b) valued credibly?
7. Were costs and consequences adjusted for differential timing?
8. Was an incremental analysis of costs and consequences of alternatives performed?
9. Was allowance made for uncertainty in the estimates of costs (a) and consequences (b)?
10. Did the presentation and discussion of study results include all issues of concern to users?
Study 1 2 3 4 5 6 7 8 9 10
a b a b a b
Bosmans et al. (2007) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ x x ✓
Byford et al. (2007) ✓ ✓ ✓ ✓ ✓ ✓ 0 X* ✓ ✓ x ✓
Domino et al. (2008); Domino et al. (2009) ✓ ✓ ✓ ✓ ✓ ✓ ✓ X* ✓ x ✓ ✓
Ekers et al. (2011) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ x x ✓
Hollinghurst et al. (2014) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ ✓ ✓ ✓
Knapp et al. (2008) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 0 ✓ x 0
Lynch et al. (2011) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ ✓ ✓ ✓
Maljanen et al. (2012) ✓ ✓ ✓ ✓ ✓ ✓ ✓ X* ✓ ✓ X ✓
Revicki et al. (2005) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ x x ✓
Sava et al. (2009) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ X X ✓
Schene et al. (2007) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ ✓ X ✓
Shimodera et al. (2012) ✓ ✓ ✓ ✓ ✓ ✓ ✓ 0 ✓ ✓ X ✓
Stant et al. (2009) ✓ ✓ ✓ ✓ ✓ ✓ ✓ x ✓ ✓ x ✓
Wade et al. (2008) ✓ 0 ✓ ✓ ✓ ✓ ✓ 0 ✓ ✓ x ✓
Note: yes ✓, no X, explanation is given why costs and consequences are not discounted X*, cannot tell 0.
Fig. 2. Risk of bias assessment.
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591 121/QALY [US$ 458 818/QALY]) at 12 weeks.
Results from the same trial indicated that the combin-
ation of fluoxetine plus CBT became more cost-
effective than fluoxetine alone over a longer follow-up
of 36 weeks (>90% probability at a threshold of US$
128 836 [US$ 100 000]). The authors concluded combin-
ation therapy is both clinically effective and cost-
effective (Domino et al. 2009).
Byford et al. (2007) studied whether CBT in addition
to SSRI treatment was cost-effective in UK adolescents
attending outpatient mental health clinics, who had
not responded to an initial brief intervention.
Compared with TAU, at 28 weeks there was no signifi-
cant difference in costs or clinical outcomes though
there was a trend towards higher costs and worse clin-
ical outcomes for combination therapy. Lynch et al.
(2011) studied CBT as an add-on to medication switch
in young people with SSRI-resistant depression.
Addition of CBT to medication switch was associated
with higher costs but also higher gains in depression-
free days at 24 weeks compared with medication
switch alone (Incremental Cost Effectiveness Ratio –
ICER of US$ 221 [US$ 188] per depression-free day
or US$ 92 812/QALY [US$ 78 948/QALY]).
Sava et al. (2009) examined CBT, REBT and fluoxet-
ine individually and followed patients for 6 months
after completion of the intervention. The authors did
not find significant differences between treatment
groups in depression severity, depression- free days
or QALYs. Due to lower costs, the psychotherapeutic
interventions were more cost-effective than fluoxetine
at US$ 4375/QALY [US$ 1638/QALY] and US$ 4632/
QALY [US$ 1734/QALY] for CBT and REBT, respect-
ively, against US$ 6109/QALY [US$ 2287/QALY] for
fluoxetine (before v. after treatment).
Among low-income ethnic minority women with
major depression in Washington DC, Revicki et al.
(2005) compared either pharmacotherapy (paroxetine
potentially followed by bupropion) or CBT with ‘com-
munity’ referral, consisting of education about depres-
sion and its treatment along with referral to usual
providers of mental health care services in the commu-
nity. At 12-month follow-up, pharmacotherapy was
slightly more cost-effective than CBT (US$ 39 570/
QALY [US$ 30 023/QALY] v. US$ 49 514 [US$ 37 568/
QALY]) compared with community referral.
Direct comparison between antidepressant agents
Only one study examined differences between various
antidepressant medications. Wade et al. (2008) exam-
ined the cost-effectiveness of escitalopram compared
with duloxetine in treating patients with MDD. The
authors found that treatment with duloxetine was
associated with higher cost, higher mean sick leave
and higher depression scores over the 24-week study
period (Wade et al. 2008).
Severe and refractory major depressive disorder
ECT and repetitive TMS (rTMS)
A small study of people with severe depressive epi-
sodes (n = 46) compared rTMS with ECT. In the 6
months after treatment, total costs for ECT (treatment,
services and informal care) were lower than for rTMS,
and ECT was more effective (McLoughlin et al. 2007;
Knapp et al. 2008).
Combined CBT plus TAU
A UK study compared addition of CBT to TAU with
TAU alone in primary care patients who did not re-
spond to medication for at least 6 weeks. Over 12
months, the costs of health and social care, out-of-pocket
expenses and productivity losses did not differ between
groups. However, CBT incurred an additional expense
of US$ 1270 [GBP £910] per patient and resulted in
improved outcomes within ICUR of US$ 20 817/QALY
[GBP £14 911/QALY] (Hollinghurst et al. 2014).
Discussion
Main results
The present systematic review presents a comprehen-
sive overview of health economic evidence for the vari-
ous treatment modalities for major depression. Several
economic evaluations of clinical trials have been con-
ducted in the area of major depression, covering phar-
macotherapeutic treatments as well as different types
of psychotherapeutic interventions, with some studies
comparing both. Only one study evaluated the cost-
effectiveness of ECT and transcranial magnetic
stimulation.
For moderate MDD, family psychoeducation was
considered cost-effective compared with TAU
(Shimodera et al. 2012). In contrast, Stant et al. (2009)
found that individual psychoeducation was outper-
formed by TAU in clinical effectiveness and cost-
effectiveness. The difference in the results of psychoe-
ducation could be attributed to differences in treat-
ment format (family v. individual) or to differences
in follow-up duration (9 v. 36 months). Two studies
examined CBT alone, but using different methodo-
logical approaches. Using a pre-post analysis, Sava
et al. (2009) found CBT and REBT were more cost-
effective than fluoxetine on account of their relative
input prices. In contrast, Revicki et al. (2005) found
CBT was less cost-effective than pharmacotherapy,
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compared with community referral. However it is clear
that both study design, population and setting
(Romania v. USA) are likely to play a major role in
these differences between findings.
A relatively broad literature examined the effects of
monotherapy with SSRIs and CBT, or the combination
of both in patients with moderate MDD. Domino et al.
reported the combination of CBT with SSRIs was clin-
ically effective and cost-effective compared with
monotherapy, but only in the longer term (Domino
et al. 2008, 2009). Lynch et al. (2011) showed higher
clinical gains as well as higher costs in favour of com-
bined treatment compared with monotherapy with
SSRIs. Finally, Byford et al. (2007) found no significant
differences between combined treatment and mono-
therapy in cost or clinical effectiveness. It should be
noted that the interventions, although similar, had dif-
ferences. In Lynch et al. (2011) trial CBT was added to
medication switch, while in Byford et al. (2007) trial
patients received CBT and started receiving SSRIs at
the same time. Thus, results should be interpreted
with caution due to limited comparability between
the examined trials. Concerning direct comparison be-
tween antidepressants, one study found escitalopram
dominated duloxetine (Wade et al. 2008).
Importantly, for several interventions (behavioural
activation, occupational therapy, short-term psycho-
logical therapies, IPT) only results from a single
study were identified (Bosmans et al. 2007; Schene
et al. 2007; Maljanen et al. 2012) limiting the generalis-
ability of conclusions. With regard to severe and re-
fractory MDD, only two clinical studies of different
interventions were identified (Knapp et al. 2008;
Hollinghurst et al. 2014), and consequently no general-
isations can be made.
Quality of economic evaluations
The overall methodological quality of the included
economic evaluations was relatively high. The major-
ity of studies described the methods in a transparent
way, reducing possible biases related to methodology
of economic outcomes assessment. However, the
results of the trial-based economic evaluations rely
heavily on the methodology of the RCTs. Thus, we
examined the included RCTs for a spectrum of pos-
sible sources of bias related to the methodology. The
results of the risk-of- bias assessment indicated that
the included studies presented overall low risk of
bias in most of the items examined except for blinding
of personnel and participants, since this type of blind-
ing is inherently difficult or impossible following ex-
posure to active psychotherapeutic interventions.
Therefore, the conclusions of the present systematic
review should be interpreted with caution due to
high risk of performance bias.
Strengths and limitations
One of the strengths of the present review is the sys-
tematic method employed to reduce the risk of bias
and to provide reliable findings and conclusions.
Moreover, this paper examined the validity of the
included studies and presents a detailed quality ap-
praisal. However, the work also has several limita-
tions. A formal meta-analysis could not be conducted
due to the high diversity in outcomes across the
included studies. Moreover, this heterogeneity of
results limited the comparability of the findings and
our ability to draw robust conclusions regarding rela-
tive cost-effectiveness of interventions. Finally, it
should be noted that the cost effectiveness of a particu-
lar intervention might differ substantially between
countries due to variations in usual care, differences
in the way new treatments are introduced, and in
costs of inputs such as the salaries of health profes-
sionals between countries. Thus, the present findings
should be interpreted with caution, and clinicians
and policy makers should take into account any na-
tional or regional evidence in order to draw conclu-
sions about the cost effectiveness of an intervention
for major depression.
Evidence gaps and future research
Little is known about the economics of occupational
therapy, short-term psychological therapies, behav-
ioural activation, PDT, REBT and IPT for the treatment
of moderate MDD and/or prevention of progression to
more severe disease. Additionally, little empirical evi-
dence is available on the cost-effectiveness of treatment
options for severe MDD. There are gaps in knowledge
regarding which medication is likely to be most cost-
effective and for which patient groups, and which psy-
chological therapy is to be preferred. There is also rela-
tively little information on the long-term impact of
treatments. No published evidence was identified
regarding the cost-effectiveness of self-help pro-
grammes delivered through the Internet by therapists
or healthcare workers other than qualified psy-
chotherapists. Similar trials are ongoing in this area,
such as Internet-delivered treatment for individuals
with depressive symptoms (Warmerdam et al. 2010),
which may provide a cost-effective approach to limit-
ing disease progression with early intervention.
The present review, and earlier draft stages, formed
part of the WHO Research Agenda for Health
Economic Evaluation project, where priorities for eco-
nomic research in mental health and nine other subject
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areas were discussed by a panel of experts (Tordrup
et al. 2015). Suggested research priorities for MDD,
based on the limitations of the available evidence, in-
clude: economic primary studies of rarely evaluated
interventions (e.g. self-help interventions); long-term
head-to-head comparisons of well studied treatments
(e.g. CBT, CBT in combination with SSRIs) against
usual care, using routinely available real-world data;
analysis of the disease course to enable prediction of
progression, thereby ensuring treatments are targeted
at those unlikely to recover naturally; and elucidation
of genetic components to treatment response.
Importantly, when considering interventions that are
supported by extensive evidence and are known to
work in treating depression, the next step should be
to target patients most likely to respond.
Conclusions
In conclusion, there is some economic evidence under-
pinning many of the interventions routinely used to
treat major depressive disorder. Wide variability was
observed in study outcomes, probably attributable to
differences in population, interventions or follow-up
periods. Significant economic evidence gaps remain
in the area of major depressive disorder.
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